News articles about CareDx (NASDAQ:CDNA) have trended positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CareDx earned a news sentiment score of 0.29 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.4252116269409 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
CareDx (CDNA) traded up $0.01 during mid-day trading on Wednesday, reaching $5.76. The company had a trading volume of 30,000 shares, compared to its average volume of 193,581. The company has a market cap of $165.90, a PE ratio of -3.18 and a beta of 0.72. CareDx has a fifty-two week low of $0.76 and a fifty-two week high of $7.98. The company has a debt-to-equity ratio of -124.53, a current ratio of 0.55 and a quick ratio of 0.35.
Several research firms recently weighed in on CDNA. ValuEngine upgraded CareDx from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of CareDx in a research report on Wednesday, January 31st. Finally, Zacks Investment Research cut CareDx from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. CareDx presently has an average rating of “Buy” and a consensus price target of $8.65.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.